Universal LCMS-based assay platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics using one reference antibody Guler, PhD Yuhong Ning David Haan Michael Kesling Ceyda Coruh Giuliana Mognol Tierney Phillips Kyle Hazen Wayne Volkmuth Samuel Levyīiomarkers Checkpoint blockade Epigenetics Bucheit, MS CGC Kyle Chang Shaun Forbes Sean Gordonīioinformatics Biomarkers Checkpoint blockade Targeted therapyĪnti-PD1 treatment response prediction and monitoring in non-small cell lung cancer patients using plasma cell-free DNA hydroxymethylation Use of real-world (RW) data to assess the ability of circulating cell-free tumor DNA (ctDNA) molecular response to assess therapeutic outcomes in patients with non-small cell lung cancer (NSCLC)Ĭaroline Weipert, MS Leylah Drusbosky Leslie A. Fox, PhDĬarcinogenesis Neoantigens Solid tumors Tumor antigens Vaccine Paustian, PhD Sam Bookhardt, BA Glenna B. Gunderson, PhD Mark Schmidt Christopher C. Pagel, PhDĬheckpoint blockade Immune monitoring Metabolism Tumor microenvironmentĭevelopment of a Vaccine to Intercept Oral Cancer Renee Chin, MS Xiaofei Liang, PhD Tianzhe Li Jorge de la Cerda F. Potentiation of the immune checkpoint blockade response by tumor acidosis and hypoxia modulation is predictable using molecular imaging Angus-Hill, Ph.D.īiomarkers Metabolism Solid tumors T cell Tumor microenvironment Tumor stromaĪdaptive immune receptor repertoire profiling for biomarker discoveryĪlex Chenchik, PhD Mikhail Makhanov Dongfang Hu Tianbing Liu Lester Kobzik, MDĪntibody Autoimmunity B cell Biomarkers Immune monitoring Inflammation RNA Solid tumors T cell Tumor antigens Michael Smith, Ph.D., Katie White, Richard Heil-Chapdelaine, Melinda L. Angus-Hill, Ph.D.īiomarkers, Immune Monitoring and Novel Technologiesī cell MDSC Monocyte/Macrophage Myeloid cells NK/NKT cell Solid tumors T cell T cell lineages Tumor infiltrating lymphocytes (TILs) Tumor microenvironmentĬharacterization of the tumor microenvironment in pancreatic ductal adenocarcinoma using multiplexed imaging SITC Business Meeting and Presidential TransitionĬapturing the spatial landscape of tumor and immune cell lineages in the microenvironment of human cancer tissues.Combination Therapy: Using Novel Approaches to Identify Novel Biomarkers.Combination Therapy: Applying Learnings from Past Successes and Failures.Primer on Tumor Immunology and Cancer Immunotherapy™.Mike DeWine (R) to build a $536 million plant for manufacturing metabolic formula. However, the announcement of the probe comes just a few weeks after Abbott reached a deal with Ohio Gov. The DOJ has not commented on the investigation. The plant was reopened over the summer following an agreement between Abbott and the FDA, though it took another eight to ten weeks for formula to start hitting the shelves again.

Its closure led to crippling shortages in the industry that became problematic for President Biden as his administration tackled rising inflation and supply chain crises throughout 2022. Politicoreported that the Sturgis plant produced one-fifth of the nation's supply of baby formula.

The shutdown ultimately triggered a massive recall, and it was alleged by company whistleblowers that Abbott had covered up food safety violations from the FDA prior to the plant's shuttering. Two of these babies would eventually die from the infections.

The investigation comes almost one year after Abbott shut down its infant formula manufacturing plant in Sturgis, Michigan, after four babies became sick with bacterial infections after consuming the products.

Sue brock abbott diagnostics